Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06921993 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Lung Ultrasound for Guiding Antibiotic Use in Pediatric Pneumonia

Study acronym: LUSCAP
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Primary completion date: Jan 31, 2026 to Dec 31, 2027
    • Study sites: 1 to 18
    • Study completion date: Sep 30, 2026 to Jun 30, 2028
    • Start date changed from estimate of May 5, 2025 to Apr 24, 2025
  2. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Pneumonia is a major cause of illness and death in children, with an annual incidence of about 3.3 per 1,000 in those under five years old, many requiring hospitalization. The diagnosis is challenging due to the absence of a universally accepted gold standard, leading to variability in emergency settings. Current guidelines recommend diagnosis based on history and physical examination, which do not reliably differentiate pneumonia from other respiratory infections or identify whether it is bacterial or viral in nature. This uncertainty can lead to the unnecessary use of antibiotics. Commonly used chest X-rays have limitations such as low sensitivity, moderate interobserver reliability, and the inability to distinguish bacterial from viral pneumonia. In contrast, lung ultrasound has shown high sensitivity and specificity for diagnosing pneumonia in children. However, lung ultrasound also cannot reliably distinguish between bacterial and viral causes and might lead to increased antibiotic prescriptions by detecting minor lung consolidations not seen on chest X-rays. Despite these issues, lung ultrasound is widely used in pediatric pulmonary assessment. The primary objective of the study is to determine if using lung ultrasound for diagnosing pneumonia in children can reduce antibiotic prescriptions compared to the standard care approach-which mainly relies on clinical diagnosis (often supplemented by chest X-ray and blood tests in selected cases). The secondary objective is to assess how frequently lung ultrasound impacts management decisions during a single clinical visit, beyond the information provided by history and physical examination. The third objective is to compare the diagnostic accuracy of lung ultrasound-supported diagnosis with existing diagnostic methods. The study hypothesizes that lung ultrasound results can act as a decision modifier, similar to other clinical tools and examination findings. However, a lack of consensus on specific lung ultrasound parameters and their clinical correlations contributes to variability in managing suspected pneumonia, potentially leading to antibiotic overuse. Eligible participants are children aged three to ten years who are in good general condition and clinically stable, presenting with signs and symptoms of lower respiratory tract infection indicative of pneumonia. Exclusion criteria include children outside the specified age range, those recently hospitalized, those who have undergone prior chest imaging, those already on antibiotic therapy, those with severe clinical instability, and those with underlying conditions predisposing them to severe or recurrent pneumonia. These criteria help ensure that the study population represents general pediatric community-acquired pneumonia cases, avoiding biases from high-risk patients. The ultimate goal of this study is to provide evidence on whether lung ultrasound can serve as a reliable tool to guide antibiotic prescriptions, thereby reducing unnecessary antibiotic use in the management of pediatric pneumonia.
Trial Details
NCT Number NCT06921993
Lead Sponsor Meyer Children's Hospital IRCCS
Collaborators: Fondazione C.N.R./Regione Toscana "G. Monasterio", Pisa, Italy, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Gaslini Children's Hospital, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, University Hospital Padova, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università degli Studi 'G. d'Annunzio' Chieti e Pescara, Bambino Gesù Hospital and Research Institute, Santobono-Pausilpon Hospital, Asst Degli Spedali Civili Di Brescia, IRCCS Burlo Garofolo, Clinica Pediatrica Università di Novara, Hospital of Prato, Columbia University, Schneider Children's Medical Center, Israel, Yale University, University of Melbourne
Conditions
(from sponsor)
Pneumonia Childhood, Pneumonia, Lung Ultrasound, Antibiotic Stewardship
Related terms Pneumonia
Enrollment 659 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov